We spoke to Dr Benedikt Schrage (Karolinska Institute, Stockholm, Sweden) for the key findings from his prospective study examining the association between the use of implantable cardioverter defibrillators and mortality in patients with heart failure. He also discusses how physicians might incorporate these findings into routine practice.
Speaker’s Disclosures: Benedikt Schrage has received funding from the German Research Foundation and received speaker’s fees from AstraZeneca.
1. What were the key findings from your prospective study that examined the association between implantable cardioverter-defibrillator use and mortality in patients with heart failure? (0:05)
2. How should physicians incorporate these observations into routine practice when considering implantable devices for their patients with heart failure? (1:20)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Heart Failure
Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]
Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]
Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021. Questions What are the challenges in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!